Diligence memo · auto-generated · as of July 2, 2026
Toby, Inc.
Toby, Inc. looks over-valued against its niche peers and is active on financing cadence.
Businessfiled
Toby, Inc. operates in Biotechnology, based in WILMINGTON.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Toby, Inc. has raised $1.4M in disclosed capital across 2 recorded rounds, aggregated from public filings. Its latest round is modeled as Pre-Seed (a round under $1.0M).
Largest single filing: $815K on 2025-05-30.
Most recent recorded round closed around 2025-05-30.
Valuation (modeled)modeled
Provath models Toby, Inc. at approximately $2.1M (range $435K–$5.4M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Over-valued. Modeled value is 2.18× the median modeled value of Pre-Seed Biotechnology companies in 2025–2027 (78 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 5 months.
Last raise 13 mo ago; this sector typically re-raises about every 14 months.
Raising on or ahead of the sector's normal rhythm.
The last round stepped up 1.4× from the prior — scaling.
Comparablesmixed
Capital scale ranks ahead of 22% of Biotechnology peers (4291 compared).
Modeled value ranks above 5% of those peers.
Closest niche peers: Illexcor Holdings, LLC, Reprogram Biosciences, Inc., Maxymune Therapeutics, Inc., EnZeta Immunotherapies, Inc., Eliaz Therapeutics Inc..
Peoplefiled
5 named people on file across officers, directors and signatories.
Risks & flagsmixed
Modeled above niche peers — valuation risk on entry.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.